HIV Reverse Transcriptase

Antiviral Agents
SJ-3366, a Unique and Highly Potent Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) That Also Inhibits HIV-2
Robert W. Buckheit, Karen Watson, Valerie Fliakas-Boltz, Julie Russell, Tracy L. Loftus, Mark C. Osterling, Jim A. Turpin, Luke A. Pallansch, E. Lucile White, J.-W. Lee, S.-H. Lee, J.-W. Oh, H.-S. Kwon, S.-G. Chung, E.-H. Cho
Antiviral Agents
Molecular Modeling Approach to Understanding the Mode of Action of l-Nucleosides as Antiviral Agents
Kyeong Lee, Chung K. Chu
Antiviral Agents
Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates
Peter R. Meyer, Suzanne E. Matsuura, Raymond F. Schinazi, Antero G. So, Walter A. Scott
Antiviral Agents
In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine
Holly Z. Bazmi, Jennifer L. Hammond, Socrates C. H. Cavalcanti, Chung K. Chu, Raymond F. Schinazi, John W. Mellors
LETTERS TO THE EDITOR
Response to Antiretroviral Therapy in a Patient with an Uncommon Codon 69 Insertion in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Paolo Bonfanti, Ivano Faggion, Simona La Seta Catamancio, Michela Violin, Claudia Balotta, Stefano Rusconi
Antiviral Agents
Selective Interaction of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Nonnucleoside Inhibitor Efavirenz and Its Thio-Substituted Analog with Different Enzyme-Substrate Complexes
Giovanni Maga, Daniela Ubiali, Raul Salvetti, Massimo Pregnolato, Silvio Spadari
Antiviral Agents
A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V
Kurt Hertogs, Stuart Bloor, Veronique De Vroey, Christel van den Eynde, Pascale Dehertogh, Anja van Cauwenberge, Martin Stürmer, Timothy Alcorn, Scott Wegner, Margriet van Houtte, Veronica Miller, Brendan A. Larder
Antiviral Agents
Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
L. M. Demeter, R. W. Shafer, P. M. Meehan, J. Holden-Wiltse, M. A. Fischl, W. W. Freimuth, M. F. Para, R. C. Reichman
Antiviral Agents
Mechanism of Inhibition of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by d4TTP: an Equivalent Incorporation Efficiency Relative to the Natural Substrate dTTP
Joseph A. Vaccaro, K. Mark Parnell, Stephanie A. Terezakis, Karen S. Anderson
Antiviral Agents
Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1
Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers, Susan Jeffrey, Lee T. Bacheler, Ronald M. Klabe, Sharon Diamond, Chii-Ming Lai, Shelley R. Rabel, Jo Anne Saye, Stephen P. Adams, George L. Trainor, Paul S. Anderson, Susan K. Erickson-Viitanen

Pages